1616831-08-3

Upstream product

• 103061-58-1 2-bromoethyl (2-bromophenyl)methyl ether 

Downstream Products

• 1616831-09-4 6-(2-((2-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)ethoxy)methyl)phenyl)-8-((2-(trimethylsilyl)ethoxy)methoxy)-3-((2-(trimethylsilyl)ethoxy)methyl)quinazolin-4(3H)-one 
• 1616831-07-2 8-hydroxy-6-(2-((2-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)ethoxy)methyl)phenyl)quinazolin-4(3H)-one 2,2,2-trifluoroacetate 

Relevant academic research and scientific papers

COMT INHIBITORS

The present invention relates to compounds of formula (I), wherein the substituents are described in claim 1 and to the pharmaceutically acceptable salts thereof. These compounds inhibit the enzyme catechol-O-methyltransferase (COMT). The compounds may be used for the treatment of Parkinson's disease, depression, cognitive impairment and motor symptoms, resistant depression, cognitive impairment, mood and negative symptoms of schizophrenia.